Symbol
| SMYD2
| contributors: mct/npt/pgu - updated : 07-11-2018
|
HGNC name
| SET and MYND domain containing 2
|
HGNC id
| 20982
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
|  
| loss of function
|
results in the loss of HSP90AA1 methylation, impaired titin stability, and altered muscle function | constitutional
|  
|  
| --low
|  
|
by promoter DNA methylation is associated with abdominal aortic aneurysm (AAA) | tumoral
|  
|  
| --over
|  
|
at significantly higher levels in breast cancer cell lines and in breast tumor tissues | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | digestive | oesophagus | |
prognosticator and potential therapeutic target in esophageal squamous cell carcinoma | cancer | digestive | pancreas | |
inhibition of SMYD2 cooperates with standard chemotherapy to treat PDAC cells and tumors |
| | | |
| Smyd2 deficiency delayed renal cyst growth in postnatal kidneys from Pkd1 mutant mice |